Zeng Y - Search Results

1

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, Yang Y, Xu S, Yao H, Jiang W, Song E. Liu J, et al. Among authors: zeng y. Nat Commun. 2022 May 31;13(1):3011. doi: 10.1038/s41467-022-30569-0. Nat Commun. 2022. PMID: 35641481 Free PMC article. Clinical Trial.

2

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.

Qin T, Zeng YD, Qin G, Xu F, Lu JB, Fang WF, Xue C, Zhan JH, Zhang XK, Zheng QF, Peng RJ, Yuan ZY, Zhang L, Wang SS. Qin T, et al. Oncotarget. 2015 Oct 20;6(32):33972-81. doi: 10.18632/oncotarget.5583. Oncotarget. 2015. PMID: 26378017 Free PMC article.

3

Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.

Zeng Y, Li Q, Qin T, Li S, Jin L, Wu J, Chen K, Deng H, Rao N, Liu Q, Su F, Jia W, Yao H. Zeng Y, et al. Anticancer Res. 2017 Aug;37(8):4539-4547. doi: 10.21873/anticanres.11851. Anticancer Res. 2017. PMID: 28739750

4

ARHGAP42 promotes cell migration and invasion involving PI3K/Akt signaling pathway in nasopharyngeal carcinoma.

Hu Q, Lin X, Ding L, Zeng Y, Pang D, Ouyang N, Xiang Y, Yao H. Hu Q, et al. Among authors: zeng y. Cancer Med. 2018 Aug;7(8):3862-3874. doi: 10.1002/cam4.1552. Epub 2018 Jun 24. Cancer Med. 2018. PMID: 29936709 Free PMC article.

5

Development and validation of a nomogram in survival prediction among advanced breast cancer patients.

Zhao J, Yang Y, Pang D, Yu Y, Lin X, Chen K, Ye G, Tang J, Hu Q, Chai J, Bi Z, Ding L, Wu W, Zeng Y, Gui X, Liu D, Yao H, Wang Y. Zhao J, et al. Among authors: zeng y. Ann Transl Med. 2020 Nov;8(21):1446. doi: 10.21037/atm-20-3473. Ann Transl Med. 2020. PMID: 33313191 Free PMC article.

6

Identification of DHX36 as a tumour suppressor through modulating the activities of the stress-associated proteins and cyclin-dependent kinases in breast cancer.

Zeng Y, Qin T, Flamini V, Tan C, Zhang X, Cong Y, Birkin E, Jiang WG, Yao H, Cui Y. Zeng Y, et al. Am J Cancer Res. 2020 Dec 1;10(12):4211-4233. eCollection 2020. Am J Cancer Res. 2020. PMID: 33414996 Free PMC article.

7

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.

Gui X, Zhao J, Ding L, Chai J, Lai H, Cai Y, Luo S, Zeng Y, Wu W, Chen H, Yao H, Wang Y. Gui X, et al. Among authors: zeng y. Front Oncol. 2023 Oct 6;13:1276976. doi: 10.3389/fonc.2023.1276976. eCollection 2023. Front Oncol. 2023. PMID: 37869095 Free PMC article.

8

Ductal lavage followed by observation versus oral corticosteroids in idiopathic granulomatous mastitis: A randomized trial.

Chen X, Huang H, Huang H, Yong J, Zhu L, Chen Q, Tan L, Zeng Y, Yang Y, Zhao J, Rao N, Ding L, Wu W, Li Y, Gui X, Ye L, Xu Y, Jiang Y, Su L, Xiao Q, Cai X, Hu T, Tan C, Liu Q, Liu S, Zhao J, Wang Y, Yu F, Zhang J, Li S, Chen K. Chen X, et al. Among authors: zeng y. Nat Commun. 2024 Oct 23;15(1):9144. doi: 10.1038/s41467-024-53143-2. Nat Commun. 2024. PMID: 39443446 Free PMC article. Clinical Trial.

9

Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study.

Gong C, Xia Y, Zhu Y, Yang Y, Lin Q, Liu Q, Yang W, Ling L, Zhong J, Duan Z, Zeng Y, Cheng Z, Shen J, Zeng Y, Chow LWC, Song E. Gong C, et al. Among authors: zeng y. Cell Rep Med. 2024 Nov 19;5(11):101807. doi: 10.1016/j.xcrm.2024.101807. Epub 2024 Nov 6. Cell Rep Med. 2024. PMID: 39510070 Free PMC article. Clinical Trial.

10

Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.

Zhao J, Yu Y, Ren W, Ding L, Chen Y, Yuan P, Yue J, Yang Y, Zou G, Chen T, Chai J, Zhang L, Wu W, Zeng Y, Gui X, Cai Y, Luo S, Yuan Z, Zhang K, Yao H, Wang Y. Zhao J, et al. Among authors: zeng y. MedComm (2020). 2024 Dec 20;6(1):e70031. doi: 10.1002/mco2.70031. eCollection 2025 Jan. MedComm (2020). 2024. PMID: 39712455 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,703 results

Search Page

Filters